<div class="table-responsive">
    <table class="table table-striped table-hover">
        <thead>
            <tr>
                
                <th scope="col">
                    <a href="?cresstrial=2898&amp;modal=1&amp;valnames=primary_outcome&amp;order=created_at">Created at</a>
                </th>
                <th scope="col">Source</th>
                
                <th scope="col">Raw Value</th>
                <th scope="col">Validated value</th>
            </tr>
        </thead>
        <tbody>
            
            <tr class="histvalue-row" histvalueid="390016" class="table-">
                
                <td>March 27, 2022, 4 p.m.</td>
                <td>usa</td>
                
                <td class="histvalue-container">
                    

        <p class="primary_outcome">
            In Phase 2/3 selected-dose (2-dose series), the difference in percentages of participants with seroresponse in participants ≥2 to &lt;5 years of age and participants 16 to 25 years of age from Phase 2/3 of the C4591001 study;In Phase 2/3 selected-dose (2-dose series), the difference in percentages of participants with seroresponse in participants ≥5 to &lt;12 years of age and participants 16 to 25 years of age from Phase 2/3 of the C4591001 study;In Phase 2/3 selected-dose (2-dose series), the difference in percentages of participants with seroresponse in participants ≥6 months to &lt;2 years of age and participants 16 to 25 years of age from Phase 2/3 of the C4591001;In Phase 2/3 selected-dose (3-dose series), the difference in percentages of participants with seroresponse in participants ≥2 to &lt;5 years of age and participants 16 to 25 years of age from Phase 2/3 of the C4591001 study;In Phase 2/3 selected-dose (3-dose series), the difference in percentages of participants with seroresponse in participants ≥6 months to &lt;2 years of age and participants 16 to 25 years of age from Phase 2/3 of the C4591001;Percentage of participants in Phase 1 reporting adverse events;Percentage of participants in Phase 1 reporting local reactions;Percentage of participants in Phase 1 reporting serious adverse events;Percentage of participants in Phase 1 reporting systemic events;Percentage of participants in Phase 2/3 reporting adverse events;Percentage of participants in Phase 2/3 reporting local reaction;Percentage of participants in Phase 2/3 reporting serious adverse events;Percentage of participants in Phase 2/3 reporting systemic events;Ph 2/3 selected-dose (2-dose series), immunobridging of SARS-CoV-2 serum neutralizing titers after 2 doses in participants ≥2 to &lt;5 years to the geometric mean of SARS-CoV-2 serum neutralizing titers in participants 16 to 25 years in the C4591001 study;Ph 2/3 selected-dose (2-dose series), immunobridging of SARS-CoV-2 serum neutralizing titers after 2 doses in participants ≥5 to &lt;12 years to the geometric mean of SARS-CoV-2 serum neutralizing titers in participants 16 to 25 years in the C4591001 study;Ph 2/3 selected-dose (2-dose series), immunobridging of SARS-CoV-2 serum neutralizing titers after 2 doses in participants ≥6 months to &lt;2 years to the geometric mean of SARS-CoV-2 serum neutralizing titers in participants 16 to 25 in C4591001 study;Ph 2/3 selected-dose (3-dose), immunobridging SARS-CoV-2 serum neutralizing titers after 3 doses in participants ≥6 months to &lt;2 years to the geometric mean of SARS-CoV-2 serum neutralizing titers in C4591001 participants 16 to 25 in study after 2 doses;Ph 2/3 selected-dose (3-dose series), immunobridging of SARS-CoV-2 serum neutralizing titers after 3 doses in participants ≥2 to &lt;5 years to the geometric mean of SARS-CoV-2 serum neutralizing titers in C4591001 participants 16 to 25 years after 2 doses
        </p>
    

                </td>
                <td class="histvalue-container">
                    

        <p class="primary_outcome validated">
            In Phase 2/3 selected-dose (2-dose series), the difference in percentages of participants with seroresponse in participants ≥2 to &lt;5 years of age and participants 16 to 25 years of age from Phase 2/3 of the C4591001 study;In Phase 2/3 selected-dose (2-dose series), the difference in percentages of participants with seroresponse in participants ≥5 to &lt;12 years of age and participants 16 to 25 years of age from Phase 2/3 of the C4591001 study;In Phase 2/3 selected-dose (2-dose series), the difference in percentages of participants with seroresponse in participants ≥6 months to &lt;2 years of age and participants 16 to 25 years of age from Phase 2/3 of the C4591001;In Phase 2/3 selected-dose (3-dose series), the difference in percentages of participants with seroresponse in participants ≥2 to &lt;5 years of age and participants 16 to 25 years of age from Phase 2/3 of the C4591001 study;In Phase 2/3 selected-dose (3-dose series), the difference in percentages of participants with seroresponse in participants ≥6 months to &lt;2 years of age and participants 16 to 25 years of age from Phase 2/3 of the C4591001;Percentage of participants in Phase 1 reporting adverse events;Percentage of participants in Phase 1 reporting local reactions;Percentage of participants in Phase 1 reporting serious adverse events;Percentage of participants in Phase 1 reporting systemic events;Percentage of participants in Phase 2/3 reporting adverse events;Percentage of participants in Phase 2/3 reporting local reaction;Percentage of participants in Phase 2/3 reporting serious adverse events;Percentage of participants in Phase 2/3 reporting systemic events;Ph 2/3 selected-dose (2-dose series), immunobridging of SARS-CoV-2 serum neutralizing titers after 2 doses in participants ≥2 to &lt;5 years to the geometric mean of SARS-CoV-2 serum neutralizing titers in participants 16 to 25 years in the C4591001 study;Ph 2/3 selected-dose (2-dose series), immunobridging of SARS-CoV-2 serum neutralizing titers after 2 doses in participants ≥5 to &lt;12 years to the geometric mean of SARS-CoV-2 serum neutralizing titers in participants 16 to 25 years in the C4591001 study;Ph 2/3 selected-dose (2-dose series), immunobridging of SARS-CoV-2 serum neutralizing titers after 2 doses in participants ≥6 months to &lt;2 years to the geometric mean of SARS-CoV-2 serum neutralizing titers in participants 16 to 25 in C4591001 study;Ph 2/3 selected-dose (3-dose), immunobridging SARS-CoV-2 serum neutralizing titers after 3 doses in participants ≥6 months to &lt;2 years to the geometric mean of SARS-CoV-2 serum neutralizing titers in C4591001 participants 16 to 25 in study after 2 doses;Ph 2/3 selected-dose (3-dose series), immunobridging of SARS-CoV-2 serum neutralizing titers after 3 doses in participants ≥2 to &lt;5 years to the geometric mean of SARS-CoV-2 serum neutralizing titers in C4591001 participants 16 to 25 years after 2 doses
        </p>
        
    
                </td>
            </tr>
            
            <tr class="histvalue-row" histvalueid="142855" class="table-">
                
                <td>Oct. 8, 2021, 12:30 p.m.</td>
                <td>usa</td>
                
                <td class="histvalue-container">
                    

        <p class="primary_outcome">
            In Phase 2/3 selected-dose participants, the difference in percentages of participants with seroresponse in participants ≥2 to &lt;5 years of age and participants 16 to 25 years of age from Phase 2/3 of the C4591001 study;In Phase 2/3 selected-dose participants, the difference in percentages of participants with seroresponse in participants ≥5 to &lt;12 years of age and participants 16 to 25 years of age from Phase 2/3 of the C4591001 study;In Phase 2/3 selected-dose participants, the difference in percentages of participants with seroresponse in participants ≥6 months to &lt;2 years of age and participants 16 to 25 years of age from Phase 2/3 of the C4591001;Percentage of participants in Phase 1 reporting adverse events;Percentage of participants in Phase 1 reporting local reactions;Percentage of participants in Phase 1 reporting serious adverse events;Percentage of participants in Phase 1 reporting systemic events;Percentage of participants in Phase 2/3 reporting adverse events;Percentage of participants in Phase 2/3 reporting local reaction;Percentage of participants in Phase 2/3 reporting serious adverse events;Percentage of participants in Phase 2/3 reporting systemic events;Ph 2/3 selected-dose participants, immunobridging of SARS-CoV-2 serum neutralizing titers after 2 doses in participants ≥2 to &lt;5 years to the geometric mean of SARS-CoV-2 serum neutralizing titers in participants 16 to 25 years in the C4591001 study;Ph 2/3 selected-dose participants, immunobridging of SARS-CoV-2 serum neutralizing titers after 2 doses in participants ≥5 to &lt;12 years to the geometric mean of SARS-CoV-2 serum neutralizing titers in participants 16 to 25 years in the C4591001 study;Ph 2/3 selected-dose participants, immunobridging of SARS-CoV-2 serum neutralizing titers after 2 doses in participants ≥6 months to &lt;2 years to the geometric mean of SARS-CoV-2 serum neutralizing titers in participants 16 to 25 years in C4591001 study
        </p>
    

                </td>
                <td class="histvalue-container">
                    

        <p class="primary_outcome validated">
            In Phase 2/3 selected-dose participants, the difference in percentages of participants with seroresponse in participants ≥2 to &lt;5 years of age and participants 16 to 25 years of age from Phase 2/3 of the C4591001 study;In Phase 2/3 selected-dose participants, the difference in percentages of participants with seroresponse in participants ≥5 to &lt;12 years of age and participants 16 to 25 years of age from Phase 2/3 of the C4591001 study;In Phase 2/3 selected-dose participants, the difference in percentages of participants with seroresponse in participants ≥6 months to &lt;2 years of age and participants 16 to 25 years of age from Phase 2/3 of the C4591001;Percentage of participants in Phase 1 reporting adverse events;Percentage of participants in Phase 1 reporting local reactions;Percentage of participants in Phase 1 reporting serious adverse events;Percentage of participants in Phase 1 reporting systemic events;Percentage of participants in Phase 2/3 reporting adverse events;Percentage of participants in Phase 2/3 reporting local reaction;Percentage of participants in Phase 2/3 reporting serious adverse events;Percentage of participants in Phase 2/3 reporting systemic events;Ph 2/3 selected-dose participants, immunobridging of SARS-CoV-2 serum neutralizing titers after 2 doses in participants ≥2 to &lt;5 years to the geometric mean of SARS-CoV-2 serum neutralizing titers in participants 16 to 25 years in the C4591001 study;Ph 2/3 selected-dose participants, immunobridging of SARS-CoV-2 serum neutralizing titers after 2 doses in participants ≥5 to &lt;12 years to the geometric mean of SARS-CoV-2 serum neutralizing titers in participants 16 to 25 years in the C4591001 study;Ph 2/3 selected-dose participants, immunobridging of SARS-CoV-2 serum neutralizing titers after 2 doses in participants ≥6 months to &lt;2 years to the geometric mean of SARS-CoV-2 serum neutralizing titers in participants 16 to 25 years in C4591001 study
        </p>
        
    
                </td>
            </tr>
            
            <tr class="histvalue-row" histvalueid="102065" class="table-">
                
                <td>March 27, 2021, 12:31 a.m.</td>
                <td>usa</td>
                
                <td class="histvalue-container">
                    

        <p class="primary_outcome">
            In Phase 2/3 participants, Geometric Mean Ratio of SARS-CoV-2 neutralizing titers in participants in each age group at selected dose level to those 16 to 25 years of age in study C4591001;Percentage of participants in Phase 1 reporting adverse events in each dose level in each age group;Percentage of participants in Phase 1 reporting local reaction in each dose level in each age group;Percentage of participants in Phase 1 reporting serious adverse events in each dose level in each age group;Percentage of participants in Phase 1 reporting systemic events in each dose level in each age group;Percentage of participants in Phase 2/3 reporting adverse events in each dose level in each age group;Percentage of participants in Phase 2/3 reporting local reaction in each dose level in each age group;Percentage of participants in Phase 2/3 reporting serious adverse events in each dose level in each age group;Percentage of participants in Phase 2/3 reporting systemic events in each dose level in each age group
        </p>
    

                </td>
                <td class="histvalue-container">
                    

        <p class="primary_outcome validated">
            In Phase 2/3 participants, Geometric Mean Ratio of SARS-CoV-2 neutralizing titers in participants in each age group at selected dose level to those 16 to 25 years of age in study C4591001;Percentage of participants in Phase 1 reporting adverse events in each dose level in each age group;Percentage of participants in Phase 1 reporting local reaction in each dose level in each age group;Percentage of participants in Phase 1 reporting serious adverse events in each dose level in each age group;Percentage of participants in Phase 1 reporting systemic events in each dose level in each age group;Percentage of participants in Phase 2/3 reporting adverse events in each dose level in each age group;Percentage of participants in Phase 2/3 reporting local reaction in each dose level in each age group;Percentage of participants in Phase 2/3 reporting serious adverse events in each dose level in each age group;Percentage of participants in Phase 2/3 reporting systemic events in each dose level in each age group
        </p>
        
    
                </td>
            </tr>
            
        </tbody>
    </table>
</div>
Created at	Source	Raw Value	Validated value
March 27, 2022, 4 p.m.	usa	In Phase 2/3 selected-dose (2-dose series), the difference in percentages of participants with seroresponse in participants ≥2 to <5 years of age and participants 16 to 25 years of age from Phase 2/3 of the C4591001 study;In Phase 2/3 selected-dose (2-dose series), the difference in percentages of participants with seroresponse in participants ≥5 to <12 years of age and participants 16 to 25 years of age from Phase 2/3 of the C4591001 study;In Phase 2/3 selected-dose (2-dose series), the difference in percentages of participants with seroresponse in participants ≥6 months to <2 years of age and participants 16 to 25 years of age from Phase 2/3 of the C4591001;In Phase 2/3 selected-dose (3-dose series), the difference in percentages of participants with seroresponse in participants ≥2 to <5 years of age and participants 16 to 25 years of age from Phase 2/3 of the C4591001 study;In Phase 2/3 selected-dose (3-dose series), the difference in percentages of participants with seroresponse in participants ≥6 months to <2 years of age and participants 16 to 25 years of age from Phase 2/3 of the C4591001;Percentage of participants in Phase 1 reporting adverse events;Percentage of participants in Phase 1 reporting local reactions;Percentage of participants in Phase 1 reporting serious adverse events;Percentage of participants in Phase 1 reporting systemic events;Percentage of participants in Phase 2/3 reporting adverse events;Percentage of participants in Phase 2/3 reporting local reaction;Percentage of participants in Phase 2/3 reporting serious adverse events;Percentage of participants in Phase 2/3 reporting systemic events;Ph 2/3 selected-dose (2-dose series), immunobridging of SARS-CoV-2 serum neutralizing titers after 2 doses in participants ≥2 to <5 years to the geometric mean of SARS-CoV-2 serum neutralizing titers in participants 16 to 25 years in the C4591001 study;Ph 2/3 selected-dose (2-dose series), immunobridging of SARS-CoV-2 serum neutralizing titers after 2 doses in participants ≥5 to <12 years to the geometric mean of SARS-CoV-2 serum neutralizing titers in participants 16 to 25 years in the C4591001 study;Ph 2/3 selected-dose (2-dose series), immunobridging of SARS-CoV-2 serum neutralizing titers after 2 doses in participants ≥6 months to <2 years to the geometric mean of SARS-CoV-2 serum neutralizing titers in participants 16 to 25 in C4591001 study;Ph 2/3 selected-dose (3-dose), immunobridging SARS-CoV-2 serum neutralizing titers after 3 doses in participants ≥6 months to <2 years to the geometric mean of SARS-CoV-2 serum neutralizing titers in C4591001 participants 16 to 25 in study after 2 doses;Ph 2/3 selected-dose (3-dose series), immunobridging of SARS-CoV-2 serum neutralizing titers after 3 doses in participants ≥2 to <5 years to the geometric mean of SARS-CoV-2 serum neutralizing titers in C4591001 participants 16 to 25 years after 2 doses	In Phase 2/3 selected-dose (2-dose series), the difference in percentages of participants with seroresponse in participants ≥2 to <5 years of age and participants 16 to 25 years of age from Phase 2/3 of the C4591001 study;In Phase 2/3 selected-dose (2-dose series), the difference in percentages of participants with seroresponse in participants ≥5 to <12 years of age and participants 16 to 25 years of age from Phase 2/3 of the C4591001 study;In Phase 2/3 selected-dose (2-dose series), the difference in percentages of participants with seroresponse in participants ≥6 months to <2 years of age and participants 16 to 25 years of age from Phase 2/3 of the C4591001;In Phase 2/3 selected-dose (3-dose series), the difference in percentages of participants with seroresponse in participants ≥2 to <5 years of age and participants 16 to 25 years of age from Phase 2/3 of the C4591001 study;In Phase 2/3 selected-dose (3-dose series), the difference in percentages of participants with seroresponse in participants ≥6 months to <2 years of age and participants 16 to 25 years of age from Phase 2/3 of the C4591001;Percentage of participants in Phase 1 reporting adverse events;Percentage of participants in Phase 1 reporting local reactions;Percentage of participants in Phase 1 reporting serious adverse events;Percentage of participants in Phase 1 reporting systemic events;Percentage of participants in Phase 2/3 reporting adverse events;Percentage of participants in Phase 2/3 reporting local reaction;Percentage of participants in Phase 2/3 reporting serious adverse events;Percentage of participants in Phase 2/3 reporting systemic events;Ph 2/3 selected-dose (2-dose series), immunobridging of SARS-CoV-2 serum neutralizing titers after 2 doses in participants ≥2 to <5 years to the geometric mean of SARS-CoV-2 serum neutralizing titers in participants 16 to 25 years in the C4591001 study;Ph 2/3 selected-dose (2-dose series), immunobridging of SARS-CoV-2 serum neutralizing titers after 2 doses in participants ≥5 to <12 years to the geometric mean of SARS-CoV-2 serum neutralizing titers in participants 16 to 25 years in the C4591001 study;Ph 2/3 selected-dose (2-dose series), immunobridging of SARS-CoV-2 serum neutralizing titers after 2 doses in participants ≥6 months to <2 years to the geometric mean of SARS-CoV-2 serum neutralizing titers in participants 16 to 25 in C4591001 study;Ph 2/3 selected-dose (3-dose), immunobridging SARS-CoV-2 serum neutralizing titers after 3 doses in participants ≥6 months to <2 years to the geometric mean of SARS-CoV-2 serum neutralizing titers in C4591001 participants 16 to 25 in study after 2 doses;Ph 2/3 selected-dose (3-dose series), immunobridging of SARS-CoV-2 serum neutralizing titers after 3 doses in participants ≥2 to <5 years to the geometric mean of SARS-CoV-2 serum neutralizing titers in C4591001 participants 16 to 25 years after 2 doses
Oct. 8, 2021, 12:30 p.m.	usa	In Phase 2/3 selected-dose participants, the difference in percentages of participants with seroresponse in participants ≥2 to <5 years of age and participants 16 to 25 years of age from Phase 2/3 of the C4591001 study;In Phase 2/3 selected-dose participants, the difference in percentages of participants with seroresponse in participants ≥5 to <12 years of age and participants 16 to 25 years of age from Phase 2/3 of the C4591001 study;In Phase 2/3 selected-dose participants, the difference in percentages of participants with seroresponse in participants ≥6 months to <2 years of age and participants 16 to 25 years of age from Phase 2/3 of the C4591001;Percentage of participants in Phase 1 reporting adverse events;Percentage of participants in Phase 1 reporting local reactions;Percentage of participants in Phase 1 reporting serious adverse events;Percentage of participants in Phase 1 reporting systemic events;Percentage of participants in Phase 2/3 reporting adverse events;Percentage of participants in Phase 2/3 reporting local reaction;Percentage of participants in Phase 2/3 reporting serious adverse events;Percentage of participants in Phase 2/3 reporting systemic events;Ph 2/3 selected-dose participants, immunobridging of SARS-CoV-2 serum neutralizing titers after 2 doses in participants ≥2 to <5 years to the geometric mean of SARS-CoV-2 serum neutralizing titers in participants 16 to 25 years in the C4591001 study;Ph 2/3 selected-dose participants, immunobridging of SARS-CoV-2 serum neutralizing titers after 2 doses in participants ≥5 to <12 years to the geometric mean of SARS-CoV-2 serum neutralizing titers in participants 16 to 25 years in the C4591001 study;Ph 2/3 selected-dose participants, immunobridging of SARS-CoV-2 serum neutralizing titers after 2 doses in participants ≥6 months to <2 years to the geometric mean of SARS-CoV-2 serum neutralizing titers in participants 16 to 25 years in C4591001 study	In Phase 2/3 selected-dose participants, the difference in percentages of participants with seroresponse in participants ≥2 to <5 years of age and participants 16 to 25 years of age from Phase 2/3 of the C4591001 study;In Phase 2/3 selected-dose participants, the difference in percentages of participants with seroresponse in participants ≥5 to <12 years of age and participants 16 to 25 years of age from Phase 2/3 of the C4591001 study;In Phase 2/3 selected-dose participants, the difference in percentages of participants with seroresponse in participants ≥6 months to <2 years of age and participants 16 to 25 years of age from Phase 2/3 of the C4591001;Percentage of participants in Phase 1 reporting adverse events;Percentage of participants in Phase 1 reporting local reactions;Percentage of participants in Phase 1 reporting serious adverse events;Percentage of participants in Phase 1 reporting systemic events;Percentage of participants in Phase 2/3 reporting adverse events;Percentage of participants in Phase 2/3 reporting local reaction;Percentage of participants in Phase 2/3 reporting serious adverse events;Percentage of participants in Phase 2/3 reporting systemic events;Ph 2/3 selected-dose participants, immunobridging of SARS-CoV-2 serum neutralizing titers after 2 doses in participants ≥2 to <5 years to the geometric mean of SARS-CoV-2 serum neutralizing titers in participants 16 to 25 years in the C4591001 study;Ph 2/3 selected-dose participants, immunobridging of SARS-CoV-2 serum neutralizing titers after 2 doses in participants ≥5 to <12 years to the geometric mean of SARS-CoV-2 serum neutralizing titers in participants 16 to 25 years in the C4591001 study;Ph 2/3 selected-dose participants, immunobridging of SARS-CoV-2 serum neutralizing titers after 2 doses in participants ≥6 months to <2 years to the geometric mean of SARS-CoV-2 serum neutralizing titers in participants 16 to 25 years in C4591001 study
March 27, 2021, 12:31 a.m.	usa	In Phase 2/3 participants, Geometric Mean Ratio of SARS-CoV-2 neutralizing titers in participants in each age group at selected dose level to those 16 to 25 years of age in study C4591001;Percentage of participants in Phase 1 reporting adverse events in each dose level in each age group;Percentage of participants in Phase 1 reporting local reaction in each dose level in each age group;Percentage of participants in Phase 1 reporting serious adverse events in each dose level in each age group;Percentage of participants in Phase 1 reporting systemic events in each dose level in each age group;Percentage of participants in Phase 2/3 reporting adverse events in each dose level in each age group;Percentage of participants in Phase 2/3 reporting local reaction in each dose level in each age group;Percentage of participants in Phase 2/3 reporting serious adverse events in each dose level in each age group;Percentage of participants in Phase 2/3 reporting systemic events in each dose level in each age group	In Phase 2/3 participants, Geometric Mean Ratio of SARS-CoV-2 neutralizing titers in participants in each age group at selected dose level to those 16 to 25 years of age in study C4591001;Percentage of participants in Phase 1 reporting adverse events in each dose level in each age group;Percentage of participants in Phase 1 reporting local reaction in each dose level in each age group;Percentage of participants in Phase 1 reporting serious adverse events in each dose level in each age group;Percentage of participants in Phase 1 reporting systemic events in each dose level in each age group;Percentage of participants in Phase 2/3 reporting adverse events in each dose level in each age group;Percentage of participants in Phase 2/3 reporting local reaction in each dose level in each age group;Percentage of participants in Phase 2/3 reporting serious adverse events in each dose level in each age group;Percentage of participants in Phase 2/3 reporting systemic events in each dose level in each age group